Please login to the form below

Not currently logged in
Email:
Password:

J&J’s clinical research neuroscience director joins MedAvante

Dr Michael Ropacki becomes head of R&D at the clinical data service

MedAvante Dr Michael RopackiGlobal clinical data services company MedAvante has appointed Dr Michael Ropacki as vice president of research and development.

Dr Ropacki joins MedAvante from Johnson & Johnson, where he served as clinical research neuroscience director in its Janssen research and development arm.

Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013.

He also brings experience as associate director and principal clinical scientist at Johnson & Johnson's biotech Centocor, which he first joined as a clinical scientist in 2004.

Paul Gilbert, MedAvante's chief executive officer, said: “Michael Ropacki is widely recognised for the groundbreaking trial methodology he has implemented for registries and prospective cohort studies.

“He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition to MedAvante's scientific leadership team.”

24th February 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Tapping the potential of rare diseases: A journey into uncharted territory
...
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...

Infographics